Drugs / HBI 0201-ESO TCRT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05296564 | Apr 2022 → Dec 2027 expected | metastatic malignant neoplasm, metastatic melanoma, neuroblastoma, non-small cell lung carcinoma +4 | Hadassah Medical Organization | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBI 0201-ESO TCRT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05296564 ↗ |
| Modality | Cell therapy | “TCR-Gene Engineered Lymphocytes” NCT05296564 ↗ |
| Route | Other | “HBI 0201-ESO TCRT will be infused on Day 0” NCT05296564 ↗ |